<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>The Trypanosoma cruzi Protease Cruzain Mediates <br /> Immune Evasion <br /> Patricia S. Doyle*, Yuan M. Zhou, Ivy Hsieh, Doron C. Greenbaum&#194;&#164;, James H. McKerrow, Juan C. Engel <br /> Tropical Disease Research Unit Sandler Center Drug Discovery, Department Pathology, University California, San Francisco, California, United States America <br />  <br />  <br />  <br />      Abstract <br />      Trypanosoma cruzi causative agent Chagas&#226;&#8364;&#8482; disease. Novel chemotherapy drug K11777 targets major <br />      cysteine protease cruzain disrupts amastigote intracellular development.  biological role      protease infection pathogenesis remains unclear cruzain gene knockout failed genetic redundancy. role <br />      T. cruzi cysteine protease cruzain immune evasion elucidated comparative study parental wild type- <br />      cruzain-deficient parasites. Wild type T. cruzi did activate host macrophages early infection (,60 min)      increase ,P ikB detected. signaling factor NF-kB P65 colocalized cruzain cell surface      intracellular wild type parasites, proteolytically cleaved. significant 12 expression occurred macrophages <br />      infected wild type T. cruzi treated <span id='am-11' about='obo:IMR_0001655' typeof='owl:Thing obo:IMR_0001790 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0000001 obo:IMR_0001362'><span id='am-12' property="obo:IAO_0000115" content="Lipopolysaccharide (LPS) is a glycosylated lipid on the outer surface of Gram-negative bacteria acts as immunostimulants." datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasDbXref" content="CHEBI:16412" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasExactSynonym" content="lipopolysaccharide" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasDbXref" content="MeSH:D008070" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="LPS" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="KEGG:C00338" datatype="xsd:string"></span><span id='am-19' property="rdfs:label" content="lipopolysaccharide" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:id" content="IMR:0001655" datatype="xsd:string"></span>LPS</span> BFA, confirming impairment macrophage activation pathways. <br />      contrast, cruzain-deficient parasites induced macrophage activation, detectable ikB phosphorylation, nuclear NF-kB <br />      P65 localization. parasites unable develop intracellularly survive macrophages. 12 expression <br />      levels macrophages infected cruzain-deficient T. cruzi comparable LPS activated controls. cruzain <br />      hinders macrophage activation early (,60 min) stages infection, interruption NF-kB P65 mediated <br />      signaling pathway. early events allow T. cruzi survival replication, lead spread infection acute <br />      Chagas&#226;&#8364;&#8482; disease. <br />  <br />   Citation: Doyle PS, Zhou YM, Hsieh  Greenbaum DC, McKerrow JH, et al. (2011) Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion. PLoS <br />   Pathog 7(9): e1002139. doi:10.1371/journal.ppat.1002139 <br />   Editor: Ingrid Mu&#194;&#168;ller, Imperial College London, United Kingdom <br />   Received November 29, 2010; Accepted 11, 2011; Published September 1, 2011 <br />   Copyright: &#195;&#376; 2011 Doyle et al. open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Funding: NIAID TDRU AI 35707 Sandler Foundation supported work. funders role study design, data collection analysis, decision <br />   publish, preparation manuscript. <br />   Competing Interests: authors declared competing interests exist. <br />   * E-mail: Patricia.Doyle-Engel@ucsf.edu <br />   &#194;&#164; Current address: Department Pharmacology, University Pennsylvania School Medicine, Philadelphia, Pennsylvania, United States America. <br />  <br />  <br />  <br />  <br /> Introduction                                                                         cruzain involvement trypomastigote infection                                                                                      proteolytic release kinin host cells surfaces activation <br />    Trypanosoma cruzi parasitic agent Chagas&#226;&#8364;&#8482; disease                  bradykinin receptors [12&#226;&#8364;&#8220;14]. recent reports suggested <br /> affects approximately 12 million people Latin America                     cruzain mediates anti-apoptotic mechanisms T. cruzi- <br />  . Current chemotherapy nifurtimox benznidazole                         infected myocardiocytes vitro [15]. biological role cruzain unsatisfactory severe effects require medical                    intracellular amastigote stage T. cruzi Chagas&#226;&#8364;&#8482; <br /> supervision [1&#226;&#8364;&#8220;3]. T. cruzi infection classically transmitted               disease pathogenesis remains largely unknown. <br /> insect vector, reduviid bug [4]. Parasites disseminate                  Assessments role cruzain T. cruzi pathogenicity insect bite site  common clinical course Chagas&#226;&#8364;&#8482;                  hampered genetic redundancy failure gene <br /> disease, infect cardiac myocytes leading acute myocarditis                     deletion attempts [9,12,16,17]. Successful knockout cruzain <br /> chronic infection relentless cardiac failure. Fulminant disease                 gene cluster achieved <span id='am-10' about='oboInOwl:date' typeof='owl:Thing'>date</span> leading speculation commonly seen HIV infection immunosuppression.                         deletion cruzain coding genes lethal. <br /> patients immunodeficieny, parasites                        <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-4' property="rdfs:label" content="chemical" datatype="xsd:string"></span>Chemical</span> knockout cysteine protease inhibitors organs, highly fatal meningoencephalitis ensues.                   lethal T. cruzi [18]. role auto-proteolysis observations led hypothesize T. cruzi successfully evades                 cruzain activation confirmed, studies did allow host immune response, fact utilize unresponsive                       elucidation biological role protease human disease. <br /> macrophages means egress insect bite site prior                  Duschak et al. [19,20] observed lower cruzain activity protease <br /> dissemination cell types [5]. specific                            sequence alterations attenuated strains compared mechanisms immune evasion T. cruzi remain largely                              virulent parental T. cruzi, authors infectivity unknown, reports suggested major protease                      dependent cruzain expression activity [21]. T. cruzi, cruzain,  k  cruzipain, GP57/51) key factor [6,7].             alternative approach study biological role vital gene <br />    Cruzain plays biological role cell remodeling                         product examine phenotype protease-deficient <br /> transformation insect epimastigote stage T. cruzi                       organisms. generated protease deficient T. cruzi retained <br /> infectious metacyclic [8&#226;&#8364;&#8220;11]. Scharfstein collaborators                    1% cruzain activity wild type parental clone <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                                    1                       September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                       T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />   Author Summary                                                           Ethics statement <br />                                                                               study carried strict accordance Guide <br />   Trypanosoma cruzi (T. cruzi) unicellular parasite            Care Use Laboratory Animals National <br />   causes Chagas&#226;&#8364;&#8482; disease, devastating health burden                      Institutes Health. protocol approved   Latin America affecting developed                    Institutional Animal Care Use Committee University <br />   countries. Macrophages cells                   California, San Francisco (AN079928-02A). <br />   infected T. cruzi disseminate infection   tissues. parasite preferentially infects   multiplies heart muscle cells causing severe heart                Protease labeling <br />   disease death. new drug K11777 targets                      WT cruzain-deficient epimastigotes washed   vital parasite enzyme, protease cruzain. Consequently,               times PBS, counted Coulter Counter Multisizer 3 <br />   important understand enzyme doing                   (Beckman) taken equal numbers parasites/ml, lysed   infection. elucidate role protease,              5 cycles freeze-thawing, centrifuged 14,000 xg 1 h 4uC <br />   compared infection macrophages parental wild                     [22], frozen 270uC used. Fractions (105 epimasti- <br />   type parasites protease deficient T. cruzi.              gotes/lane) reacted iodinated inhibitor DCG04 <br />   report role parasitic protease immune evasion.              [27,28] electrophoresed. Resolved molecular species   protease prevents macrophage activation allow-                  isolated analyzed nano LC/MS, CID spectra,   ing T. cruzi survival replication, favoring                  fractionation MALDI-TOF Protein Facility, UCSF. <br />   spread infection.                                                     Protein fragments (9-17 aa long) analyzed NCBI blast. <br />  <br />  <br /> [22]. report cruzain deficient T. cruzi rapidly activate       Immunoelectron microscopy (IEM) <br /> host macrophages NF-kB P65 unable survive                      BESM cells infected intracellular amastigotes WT intracellularly macrophages. contrast, infection wild       cruzain-deficient T. cruzi processed IEM specific <br /> type parasites appears induce cruzain-mediated proteolysis           anti-cruzain polyclonal antibody previously described [24]. <br /> NF-kB P65 leading unresponsiveness host macrophage               Briefly, T. cruzi-infected BESM cells collected centrifuga- early (,60 minutes) infection. immune evasion                  tion, washed twice PBS fixed 2 hours 4uC 2% <br /> mechanism critical T. cruzi survival early               paraformaldehyde-0.05% glutaraldehyde 0.1 M phosphate <br /> natural infection low number trypmastigotes.                     buffer, pH 7.4. Cells cryoprotected, frozen, sectioned, <br />                                                                            immunolabeled sequentially rabbit polyclonal anti- <br />                                                                            cruzain Ab goat anti-rabbit IgG-10 nm gold-labeled Ab <br /> Materials Methods <br />                                                                            (dilutions 1:250 1:500, respectively). sections Parasites cells                                                        observed Tecnai 10 (FEI ) electron microscope. Gold- <br />    Wild type CA 72 T. cruzi isolated Argentinean             labeled cruzain localizing amastigote cell surface chronic chagasic patient cloned [23]. Cruzain-deficient,           quantified micrographs intracellular parasites cysteine protease inhibitor (K11777)-resistant (CA KR; KR) T.            independent experiments (n = 55 wild type amastigotes; n = 55 <br /> cruzi derived parental CA 72 parasites [22].               cruzain-deficient amastigotes). cell perimeter sectioned <br /> cysteine protease inhibitor K11777 (K777, N-Methyl-Pip-F-hF-               intracellular amastigotes measured Openlab software <br /> VSW) kindly provided J. Palmer, Celera, CA [18,24].                 (Improvision), cruzain density expressed number Epimastigotes maintained 26uC Brain-heart tryptose              gold labeled cruzain particles/mm parasitic cell membrane. <br /> (BHT) medium [25] 10% heat inactivated fetal calf serum               Results statistically analyzed (t test). <br /> (FCS), addition 20-fold lethal dose (200 mM) K11777 phenotypic cruzain-deficient CA KR.                           Western blots (WB) <br />    Bovine embryo skeletal muscle cells (BESM) cells kind               J774 macrophages seeded 12 tissue culture plates <br /> gift J.  Dvorak, NIH. Mammalian stages wild type (WT)              24 h prior infection WT cruzain-deficient T. cruzi CA 72 maintained BESM cells RPMI-1640                       appropriate. Infection performed low ratio 0.5 <br /> medium 5% heat inactivated horse serum (HS) 37uC                    parasites/macrophage. infected cultures treated [26]. Intracellular cruzain-deficient CA KR T. cruzi                cysteine protease inhibitor. Controls consisted J774 macrophage <br /> maintained serially BESM addition              cultures uninfected, treated purified LPS (150 ng/ <br /> 5% heat inactivated FCS, 5% heat inactivated horse serum,              ml LPS, Sigma) [29], treated K11777. Samples 10 mM K11777. Long-term culture higher concentrations            collected 1 min, 30 min, 60 min, 150 min, 48 h <br /> inhibitor toxic BESM cells. experiments,              post-infection. Monolayers washed twice cold PBS, <br /> mammalian stages cruzain-deficient CAI/KR                     solubilized 1 ml cold PBS with1% Triton X-100, scraped, <br /> cultured 4 passages (2 months) absence inhibitor.            aliquoted, immediately snap-frozen, stored 270uC approximate duration intracellular cycle wild type           used. Samples centrifuged 14,000 xg 30 min 4uC <br /> CA 72 (4.5 days) [23] CA KR (18 days) estimated             supernatants taken identical protein concentration. <br /> infected BESM cells contrast phase microscopy                    Samples (1 mg protein/lane) heated 70uC 5 min fluorescence microscopy propidium iodine stained slides.                resolved Nupage electrophoresis (10% BisTris gels 200 V, <br /> Cruzain-deficient parasites unable survive develop             Mops Buffer) (Novex, Invitrogen) prior transferring PVDF macrophages.                                                        membranes (35 V 2 h). Blots blocked overnight 1% <br />    J774 mouse macrophages UCSF cell culture                  BSA (Sigma). Samples blotted rabbit anti&#226;&#8364;&#8220;NF-kB P65 <br /> facility. J774 cells cultured experiments        Ab, rabbit anti- ikB Ab, mouse anti-phosphorylated (,P) ikB Ab <br /> irradiated (1000 Rad) 24 h prior use arrest cell division.           (Santa Cruz Biotech, CA) anti actin Ab (Cal Biochem). Normal peritoneal macrophages collected C3H mice                 methods according manufacturer&#226;&#8364;&#8482;s instructions (Santa <br />  Jackson Lab).                                                         Cruz Biotech, CA). Additional controls similarly infected <br />  <br />  <br />       PLoS Pathogens | www.plospathogens.org                           2                    September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                      T. cruzi Protease Mediates Immune Evasion <br />  <br />  Leishmania mexicana, kind gift J. Mottram (University        stained macrosialin (mouse CD68 homolog) specific Ab <br /> Glasgow, UK), 48 hours. Results confirmed duplicate           (Serotec) (Dil 1/200) followed CY2 affinity-pure donkey anti- <br /> experiments according methods described Ma                      rat IgG (Jackson Immuno-Research lab) secondary Ab PI <br /> colleagues [30&#226;&#8364;&#8220;32]. Briefly, 56106 cells point (1, 10, 30,        (Molecular Probes). <br /> 60 min) infected T. cruzi trypomastigotes (ratio <br /> 0.5 parasites/cell). Non-infected macrophages untreated            Proteolysis NF-kB P65 <br /> (MW) treated LPS, K11777 indicated (10, 20, 40             Human recombinant NF-kB P65 (rNF-kB P65) (Active Motif, 60 min) used controls. Macrophages washed           Japan) expressed E. coli length cDNA clone 14 <br /> twice PBS, scraped, transferred eppendorf tubes,              aa deletion C-term. ml rNF-kB P65 diluted centrifuged prior lysis NP40 lysis buffer (0.1% NP40,             150 nM 10 ml 1x buffer  5 ml 1M DTT/ml 5 mM <br /> 1 mM Na vanadate 5 mM Na fluoride250 mM HEPES).                       DTT) reacted recombinant cruzain 150 nM (1/ <br /> Nuclei pelleted centrifugation (20 min 14,000 xg,         1) serial dilutions (1/10 1/1000) 100 mM Na Acetate <br /> 4uC) discarded, supernatants boiled Laemli            Buffer pH 5.5 2 h 37uC. Human rNF-kB P65 buffer 10 min immediately prior SDS-PAGE/WB (Cell                  reacted sonicates 2.56105 wild type CA 72 cruzain <br /> Signalling Technology) [30,31]. Membranes developed                  deficient CA KR parasites  Samples resolved <br /> sequentially anti ,PikB Ab (Cell Signalling), anti-ikB Ab            WB anti- NF-kBP65 Ab. <br /> (Cell Signalling), anti-actin Ab (Southern Biotech) [30]. <br />                                                                           T. cruzi vitro assay <br /> Confocal microscopy                                                          better understand effect macrophage activation    Duplicates samples described WB appropriate           parasite intracellular development, macrophages infected <br /> controls simultaneously seeded 12 tissue culture           WT T. cruzi (ratio 0.5 trypomastigotes/cell) 1 h 37uC. <br /> plates containing sterile round cover glasses. 1 min, 30 min,          Cultures included untreated controls, macrophages treated <br /> 60 min, 150 min post-infection, cells washed, fixed         150 nM purified LPS [29] follows: LPS added 1 h <br /> fresh 4% paraformaldehyde PBS, rinsed PBS, treated             prior T. cruzi infection, concomitantly infection, 1 h <br /> 0.1% Triton X-100 PBS 5 min, rinsed, processed             infection. Cultures treated LPS 48 h. <br /> confocal microscopy anti -mouse NF-kB P65Ab (Dil 1/100;              Duplicate cultures fixed 4% paraformaldehyde 1 h <br /> Santa Cruz Biotech, CA) followed Alexa 488 labeled secondary            , 24 h, 48 h post-infection. Cells stained PI Ab propidium iodine (Molecular Probes). Results 3&#226;&#8364;&#8220;           mean number intracellular parasites/cell estimated 7 independent experiments (n = 2&#226;&#8364;&#8220;3 slides treatment).                 200 cells slide (n = 3 slides/treatment) independent <br /> Confocal images acquired Leica Laser Confocal                 experiments [26]. Results analyzed statistically (t test). <br /> microscope TCS-NP, using Leica software identical param- <br /> eters samples,  100X objective numerical          Cruzain L-arginase assays <br /> aperture 1.4 102461024 format, pinhole 0.7 airy,            Cruzain activity determined extracts WT cruzain- section 0.2 mm.                                                    deficient CA KR epimastigotes previously described [22].    colocalization studies cruzain NF-kB P65, macro-            L-arginase determinations [7,34], J774 uninfected controls phages infected 30 min WT T. cruzi treated            macrophages infected WT cruzain-deficient trypomasti- K11777, similarly infected cruzain-deficient T. cruzi        gotes used. Cells collected 48 h post-infection treated K11777, non-infected controls            samples fixed 4% paraformaldehyde counting Coulter <br /> fixed stained sequentially rabbit anti-NF-kB P65 Ab (Dil         Counter Multisizer 3 (Beckman). Aliquots corresponding 1/100; Santa Cruz Biotech) Alexa 488-labeled secondary Ab,            105cells/50 ml prepared duplicate L-arginase assays <br /> followed rabbit polyclonal anti-cruzain antibody (Dil 1/100)           described Stempin et al. [7] Briefly, cells lysed 0.1% <br /> [24] previously labeled Alexa 594 according manufactur-           Triton X-100 buffer protease inhibitors, centrifuged er&#226;&#8364;&#8482;s instructions (Molecular Probes).                                     14,000 xg 30 min 4uC, supernatants stored 270uC. <br />    confocal studies IL12 expression, macrophages treated        L-arginase activity supernatants determined described K11777 infected WT cruzain-deficient T.             [7,34]. <span id='am-47' about='obo:IMR_0200111' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-48' property="rdfs:label" content="Urea" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:id" content="IMR:0200111" datatype="xsd:string"></span><span id='am-51' property="oboInOwl:hasDbXref" content="KEGG:C00086" datatype="xsd:string"></span>Urea</span> (mg/ml) measured 540 nm. Results cruzi 1 h (ratio 0.5 trypomastigotes/macrophage) followed          independent experiments (n = 3 sample) analyzed <br /> overnight incubation fresh RPMI medium 37uC. Cultures             statistically Prism 4 software. exposed 150 ng/ml purified LPS 2 h (Sigma), <br /> followed 5 mg/ml BFA (Molecular Probes) 1 h 37uC.               Results <br /> Appropriate controls included independent exper- <br /> iments (n = 2 sample). Slides fixed            Cruzain-deficient T. cruzi <br /> simultaneously stained anti-IL12 antibody (1/100) (R<span id='am-31' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-32' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-34' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-35' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span>amp</span>;D                  cysteine protease inhibitor K11777 cidal WT T. cruzi. <br /> Systems) [33] 1 h followed secondary Cy2-labeled                   exposing CA 72 T. cruzi gradual step-wise micromolar <br /> secondary Ab (dil 1/1000) (Biomed) propidium iodine (PI)              increases K11777 concentration period 2 years, (Dil 1/5000) (Molecular Probes). Coverslips mounted             generated K11777-resistant cruzain-deficient T. cruzi Vecta-Shield (Vector Lab). slides observed                   retains negligible (,1%) protease activity detected documented day Leica microscope, model                   fluorescent protease substrate [22]. parental WT TCS-NP, using Leica software identical confocal parameters            cruzain-deficient parasites clonal populations [22]. Cruzain- described  microscopist analyzed slides blindly.         deficient T. cruzi remained resistant K11777 14 years <br /> Fluorescence analyzed quantitatively Openlab                passage animals. mechanism drug <br /> software (Improvision). Fluorescence intensity recorded            resistance described epimastigotes random (n = 12 sample) statistically analyzed (t test).           secretion inactive, unprocessed cruzain [22]. IC50 CA- <br />    additional studies, macrophages infected WT             72 epimastigotes 3&#226;&#8364;&#8220;5 mM K11777 cruzain-deficient cruzain-deficient CA KR, uninfected controls               epimastigotes routinely maintained 20-fold lethal dose  <br />  <br />       PLoS Pathogens | www.plospathogens.org                          3                    September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                         T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br /> K11777 (200 mM). IC50 values intracellular wild type                Similar results obtained methods Abs cruzain-deficient amastigotes 0.8&#226;&#8364;&#8220;1 mM 12 mM K11777,                different vendors. WB analyses anti-NF-kB P65 Ab <br /> respectively.                                                               (Figure 3A) showed expression macrophages infected WT <br />    Differing parental CA 72 T. cruzi lethal              T. cruzi 1 min 30 min post-infection (lanes 1, 4) similar <br /> doses $103 trypomastigotes, cruzain-deficient parasites              uninfected controls (lane 3), lower (lane 8) 60 min post- <br /> unable establish infection normal mice doses 106           infection. Phosphorylation ikB indicative cell activation <br /> trypomastigotes lethal severely immunodeficient           [40,45]. Samples WB heated 70uC 5 min <br /> Rag 1 2/2 mouse model Chagas&#226;&#8364;&#8482; disease (Doyle, unpublished                (Santa Cruz Biotech. methods) boiled 10 minutes <br /> data). results independently submitted                    immediately prior SDS-PAGE dissociate complexes [30&#226;&#8364;&#8220; <br /> publication.                                                                32]. Samples blotted specific anti ,PikB Abs different <br />                                                                             commercial sources using different protocols confirmed active site affinity tag identifies processed active                     negligible ,P ikB indicative unresponsiveness macrophages <br /> proteases wild type cruzain deficient T. cruzi                       infected WT T. cruzi 60 min uninfected controls <br />    identify compare proteases WT cruzain-deficient            (Figure 3B). contrast, ,P ikB indicative activation T. cruzi, used functional proteomic method developed                confirmed macrophages infected cruzain-deficient T. cruzi <br /> profile protease targets crude cellular extracts [27,28].            early 1 min post-infection. Additional macrophage controls <br /> iodinated probe DCG04, allowed specific identification               infected cruzain-deficient T. cruzi cultured 2 months <br /> mature, active cruzain parental WT epimastigotes                    K11777 showed intermediate results parasites <br /> following SDS-PAGE (Figure 1). Cruzain-deficient parasites                  regained partial cruzain activity, investigated <br /> expressed unprocessed inactive cruzain prodomain                   [22]. Additional controls uninfected macrophages <br /> attached previously shown WB [22] active mature                treated LPS K11777 (K77) (Figure 3D). L. <br /> protease. identity cruzain confirmed MS/MALDI                 mexicana infected controls [32], NF-kB P65 degradation NCBI blast.                                                             observed 48 h post-infection (data shown). <br />    confirm decreased cruzain expression intracel- <br /> lular pathogenic amastigote stage performed comparative,                 NF-kB translocated nucleus quantitative IEM. statistically significant (p,0.1) fold            macrophages infected cruzain-deficient parasites <br /> decrease expression membrane bound cruzain confirmed                 investigate macrophage responses WT versus intracellular cruzain-deficient amastigotes compared WT           cruzain deficient T. cruzi-infection, performed confocal studies. <br /> controls (Figure 2).                                                        NF-kB P65 localization cytoplasmic macrophage controls <br />                                                                             (Figure 4E). NF-kB P65 localization cytoplasmic Transcription factor NF-kB P65 activated                         macrophages infected WT T. cruzi 1, 30, 60 min post- <br /> macrophages infected cruzain-deficient parasites                       infection confirming unresponsiveness T. cruzi infection. <br />    proposed proteases L. mexicana cleave NF-kB          Interestingly, NF-kB P65 covered surface WT amastigotes facilitate immune evasion [35]. assayed NF-kB               early 30 min post-infection (Figure 4A&#226;&#8364;&#8220;B). Similar results <br /> activation cells recently (#60 min) infected cruzain deficient        observed BESM cells thioglycolate elicited peritoneal <br /> parasites. compared macrophage activation signaling path-                mouse macrophages (data shown). contrast, intense NF-kB <br /> ways [36&#226;&#8364;&#8220;39] consequence early infection WT versus             P65 <span id='am-46' about='rdfs:label' typeof='owl:Thing'>label</span> indicative cell activation localized nucleus cruzain-deficient T. cruzi. infection cell population T.        macrophages infected cruzain-deficient T. cruzi (Figure 4C&#226;&#8364;&#8220; <br /> cruzi follows binomial distribution, cells heavily          D) (yellow fluorescence), NF-kB P65 seen bound infected cells remain non-infected.  infection          parasites 60 min. Activation occurred macro- high ratio parasites cell results premature rupture        phage controls infected WT T. cruzi presence 10 mM heavily infected macrophages. prevent premature release           K11777 (data shown). intracellular parasites secondarily activate macro- <br /> phages population, used low infection ratio 0.5         Colocalization NF-kB cruzain <br /> parasites cell.                                                            Colocalization NF-kB P65 (green fluorescence) cruzain <br />    detect macrophage activation, performed WB targeting               (red fluorescence) cell surface intracellular parasites NF-kB family member specific inhibitor [40&#226;&#8364;&#8220;45].                  occurred macrophages infected WT T. cruzi  <br />  <br />  <br />  <br /> Figure 1. active site affinity tag identifies processed active proteases wild type cruzain deficient T. cruzi. Iodinated DCGO4 <br /> (0.1, 1, 10, 50 mM) reacted epimastigote extracts (105 epimastigotes/lane). Processed, active cruzain (47.5 kD) identified major protease wild type T. cruzi. Higher molecular species identified unprocessed cruzain MALDI active protease observed cruzain-deficient parasites 50 mM DCG04. <br /> doi:10.1371/journal.ppat.1002139.g001 <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                           4                     September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                             T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />  <br /> Figure 2. IEM confirms lack surface-associated cruzain. cruzain-specific gold-labeled secondary antibody identified cruzain cell <br /> surface intracellular wild type cruzain-deficient T. cruzi amastigotes. 3-fold (p,0.1) reduction gold-labeled Ab detection cruzain present cell surface flagellar pocket cruzain-deficient CA KR (B) versus wild type amastigotes   (45,000X). Results representative independent experiments. N, nucleus; K, kinetoplast; FP, flagellar pocket; C, cytoplasm BESM cell. <br /> doi:10.1371/journal.ppat.1002139.g002 <br />  <br />  <br />  <br />  <br /> Figure 3. Cruzain-deficient (KR) WT parasites activate NF-kB. Uninfected controls mouse macrophages (MW) infected WT KR T. cruzi infected # 1 min (lanes 1, 2), 30 minutes (lanes 3&#226;&#8364;&#8220;7) 60 minutes (lanes 8&#226;&#8364;&#8220;11). Cell extracts western blotted   anti-NF-kB P65 Ab; B, anti ,P-ikB; C, anti-actin Ab. MW infected follows: lane #1, WT; lane #2, KR; lane #3, uninfected MW; lane #4, WT; <br /> lane #5, KR; lane #6, KR 10 mM K11777; lane #7, KR cultured K777 2 months; lane #8, WT; lane #9, KR; lane #10, KR 10 mM <br /> K11777; lane #11, KR cultured K11777 2 months. Results representative independent experiments using different methods. <br /> Controls (D) MW treated K11777 LPS. <br /> doi:10.1371/journal.ppat.1002139.g003 <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                              5                      September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                         T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />  <br /> Figure 4. NF-kB P65 localizes cell surface wild type parasites. Localization NF-kB P65 (green fluorescence) investigated mouse macrophages. Parasite host cell DNA labeled PI (red). Non-infected macrophages showed evenly scattered distribution cytoplasmic NF-kB P65 (E). Intracellular WT- T. cruzi appeared coated macrophage NF-kB P65   B). contrast, abundant cytoplasmic (green <br /> fluorescence) nuclear (yellow fluorescence) NF-kB P65 occurred macrophages infected cruzain deficient T. cruzi (C&#226;&#8364;&#8220;D). Macrophages infected 30 min   C), 60 min (B, D). Results representative independent experiments. <br /> doi:10.1371/journal.ppat.1002139.g004 <br />  <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                           6                     September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                          T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />  <br /> Figure 5. Colocalization cruzain NF-kB P65. C. Representative examples colocalization labeled cruzain   (red fluorescence) NF-kB P65 (B) (green fluorescence) flagellar pocket region cell surface interiorized transforming parasites (C, merge). D. Lack colocalization accumulated cruzain (red fluorescence) NF-kB P65 (green) macrophage infected WT T. cruzi treated 10 mM K11777 induces accumulation unprocessed zymogen Golgi compartment (arrow) (22). <br /> doi:10.1371/journal.ppat.1002139.g005 <br />  <br /> trypomastigote amastigote transformation (Figure 5A&#226;&#8364;&#8220;C).                    microscopy followed fluorescence quantification Improvi- <br /> Intracellular WT T. cruzi treated trypanocidal inhibitor             sion software. Macrophages infected WT T. cruzi, K11777 30 min showed marked cruzain accumulation                          subsequently activated LPS followed BFA treatment, <br /> presumably parasitic Golgi compartment [24]                     showed negligible cytoplasmic IL12 (Figure 8A). significant <br /> recruitment NF-kB P65 parasite surface (Figure 5D,                  increase (P,0.1) IL12 accumulation occurred macrophages <br /> arrow).                                                                       infected wild type T. cruzi treated inhibitor <br />                                                                               K11777 prevents cruzain activity (Figure 8B). Similarly, <br /> Proteolysis human rNF-kB cruzain                                        activation significant IL12 accumulation occurred macro- <br />    Human rNF-kB P65 proteolytically cleaved major                phages infected cruzain-deficient T. cruzi (Figure 8C). <br /> fragments native cruzain expressed WT (Figure 6) proteases expressed cruzain-deficient T. cruzi. Similarly,                 L- arginase assays <br /> recombinant cruzain degraded human r-P65 equimolar                            investigators reported increased L-arginase activity <br /> concentrations experimental conditions used                 induced cruzain treatment cells [7]. WT parasites presence 10 mM K11777.                                              induced 2-5 fold higher L-arginase activity host macrophages <br />                                                                               cruzain-deficient parasites failed increase enzymatic <br /> T. cruzi development macrophages                                           activity (P,0.01). Representative values 3 indepen- <br />    understand effect macrophage activation [37,42]               dent experiments 3.1360.02 mg urea/ml macrophages <br /> T. cruzi intracellular survival development, performed                 infected WT parasites, 1.5660.02 mg urea/ml macro- <br /> quantitative vitro assays [26]. T. cruzi divided normally control       phages infected cruzain-deficient parasites, 1.560.01 mg <br /> macrophages mean number parasites cell (P/cell)                urea/ml uninfected macrophages. <br /> increased ,0.5 2.8 48 h (Figure 7) [23]. Activation macrophages purified LPS 1h prior concomitantly                 Discussion infection resulted parasite death. T. cruzi developed macrophages treated LPS 1h post-infection; lower mean                   complex dynamic scenario host cell-parasite <br /> P/cell probably results death parasites trapped          interactions apparent pathogens use different parasitophorus vacuole activation occurred.                     mechanisms subvert host-cell signaling pathways modulate <br /> macrophage unresponsiveness early infection (,60 min)                   kinetics intracellular development. reports <br /> crucial parasite survival intracellular development.                  T. cruzi modulates signaling pathways mammalian <br />                                                                               cells [15,43,44]. authors propose activation NF-kB <br /> IL12 expression                                                               proteins modulate tissue specificity, muscle cells   confirm macrophage unresponsiveness infection WT                 preferentially harbor T. cruzi activated [37] T. cruzi infection, investigated IL12 expression confocal          detect muscle endothelial cell activation post-infection <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                             7                    September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                                T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />  <br /> Figure 6. Proteolytic cleavage r-human NF-kB P65 wild type- r-cruzain proteases expressed cruzain- <br /> deficient T. cruzi. Recombinant human NF-kB P65 treated cruzain parasite extracts. Lane 1, untreated control; lane 2, r-cruzain <br /> (1:1 molar ratio); lanes 3&#226;&#8364;&#8220;4: dilutions 1:10 1:100 r-cruzain, respectively; lane 5, r-cruzain (1:1 molar ratio) 10 mM K11777; lane 6, WT cruzain; <br /> lane 7, proteases cruzain-deficient T. cruzi. Results representative independent experiments. <br /> doi:10.1371/journal.ppat.1002139.g006 <br />  <br /> [45,46]. investigate role protease                intensity activating signal. NF-kB complexes normally <br /> cruzain early infection (,60 min) macrophages T.                    inactive cytoplasm activation enter nucleus <br /> cruzi, particular nuclear factor NF-kB P65, using              modulate gene expression. Membrane receptors (e.g. TRL) inhibitor K11777 phenotypic cruzain knockouts [22].                          signaling regulators involved [38&#226;&#8364;&#8220;42,43&#226;&#8364;&#8220;52]. <br />    major role NF-kB family regulation aspects                 compare infection WT versus cruzain-deficient T. cruzi, innate adaptive immune responses. NF-kB members                          performed WB NF-kB P65 ,P ikB (Figure 3) [39,47] <br /> control transcription genes encoding cytokines                        showed unresponsiveness macrophages infected WT <br /> antimicrobial molecules, genes regulating cell differenti-            parasites. Confocal studies showed WT parasites rapidly <br /> ation, survival, proliferation apoptosis [38]. complex                   sequestered NF-kB P65 cell surface (Figure 4, B). <br /> response depends cell type nature, duration                Similar events occurred early infection peritoneal mouse <br />  <br />  <br />  <br />  <br /> Figure 7. Macrophage activation prevents T. cruzi intracellular development. Mouse macrophages infected wild type T. cruzi LPS added indicated. Mean parasites/cell determined 1 h 48 h post-infection. Parasite death occurred LPS added prior concomitantly T. cruzi trypomastigotes. Results representative independent experiments (n = 3 treatment). <br /> doi:10.1371/journal.ppat.1002139.g007 <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                                8                      September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                                     T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  <br />  <br /> Figure 8. 12 expression. significant IL12 expression detected macrophages infected wild type T. cruzi cells treated 10 mM K11777 significantly higher cytoplasmic IL12 levels. Increased IL12 expression occurred macrophages infected cruzain- <br /> deficient T. cruzi. Results representative independent experiments.  Wild type-infected control. B. Macrophage infected wild type T. <br /> cruzi treated 10 mM K11777. C. Macrophage infected cruzain-deficient T. cruzi. <br /> doi:10.1371/journal.ppat.1002139.g008 <br />  <br />  <br />  <br /> macrophages BESM cells (data shown). Cruzain localized                         case T. cruzi, TLR2 TLR9 receptors mediate cellular cell surface WT intracellular amastigotes (Figure 2) [53]                    activation [43,59,66,72&#226;&#8364;&#8220;73]. colocalized NF-kB P65 (Figure 5). Treatment                                 results macrophages infected WT T. cruzi <br /> K11777 caused accumulation unprocessed inactive                                 remained unresponsive early infection, support protease Golgi [24] abrogated NF-kB P65 sequestration                       hypothesis intracellular pathogens uniquely protected parasite (Figure 5D). Degradation NF-kB P65 noted                        macrophage activation [38]. Confirming results, expression <br /> 60 min infection wild-type T. cruzi (Figure 3) native                   profiling bone marrow macrophages infected T. cruzi <br /> cruzain degraded recombinant nuclear factor (Figure 6).                           revealed transcriptional changes 12 hours.  inhibition IL12 confirmed macrophage unresponsiveness                         24 hours post infection, macrophages fibroblasts early WT T. cruzi infection (Figure 8A).                                            express interferon-regulated genes [62,74,75]. L. mexicana <br />    contrast, macrophages infected cruzain-deficient T. cruzi                   cruzain homologue, &#226;&#8364;&#732;&#226;&#8364;&#732;cpb&#226;&#8364;&#8482;&#226;&#8364;&#8482;, likewise degrades NF-kB P65, IkBa, rapidly activated NF-kB P65 (Figure 3, KR)                              IkBbpreventing macrophage activation [35]. Similar strategies <br /> intense nuclear localization P65 occurred shortly infection                   suppress immune responses coccidian <br /> (Figure 4C&#226;&#8364;&#8220;D) highlighting role cruzain modulation                     parasite Theileria [76], poliovirus picornavirus host cell signaling pathways. anticipated, infection cruzain-                  viral proteases cleave NF-kB P65 generating inactive products [77]. <br /> deficient parasites induced IL12 accumulation (Figure 8C).                             hypothesize cruzain plays key role degrading NF- <br />    Preventing macrophage activation crucial successful                        kB P65 hindering activation innate phagocytes recruited infection.  wild type T. cruzi killed macrophages                     bite site [5]. Macrophage unresponsiveness favor parasite activated LPS prior infection (Figure 7),                       survival early infection delay onset immune <br /> presumably parasites contained parasito-                    response. successful macrophage infection results phorus vacuole [54&#226;&#8364;&#8220;57] susceptible cidal macrophage                         production hundreds infectious T. cruzi. example single <br /> products. macrophage metabolic pathways modu-                          CA 72 parasite originates ,130 infectious trypomastigotes just <br /> lated T. cruzi. Infection WT cruzain-deficient T. cruzi                4.5 days [23]. host immune response triggered [65&#226;&#8364;&#8220; <br /> significantly increased L-arginase activity [6,7]. similar phenome-                  67], parasite development restricted permissive tissues <br /> non occurs Leishmania infection [58]. observed                     muscle cells [37,71]. cruzain function modulation macrosialin, murine analog human CD68,                         early events macrophage infection favoring immune evasion cells infected WT T. cruzi  shown). studies                       T. cruzi. <br /> identify host cell molecules modulated T. cruzi [59&#226;&#8364;&#8220;63]. <br />    Experimental clinical evidence shows correlation                      Acknowledgments severity Chagas&#226;&#8364;&#8482; disease persistence T. cruzi                        memory James  Dvorak, NIH. thank  Ma R. Tavares tissues [64&#226;&#8364;&#8220;65]. NF-kB complexes important                          helpful discussion, C. Franklin technical assistance. K.F. <br /> development function innate adaptive immune                            Medzihradszky performed <span id='am-5' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-6' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-7' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-8' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-9' property="rdfs:label" content="peptide" datatype="xsd:string"></span>peptide</span> analyses P. Loke, FACS analysis <br /> responses triggered pathogens [38,51]. Metabolic pathways                        (data shown). innate immune induced early infection important consequences evolution disease                         Author Contributions <br /> play role control T. cruzi replication, tissue distribution                Conceived designed experiments: PSD JCE. Performed degree parasitism. infection progresses, adaptive                         experiments: PSD YMZ IH JCE. Analyzed data: PSD JCE JHM DCG. <br /> immune response develops production high levels                             Contributed reagents/materials/analysis tools: DCG. Wrote paper: <br /> inflammatory cytokines, IFNc radicals [38,59,66&#226;&#8364;&#8220;71].                         PSD. <br />  <br />  <br /> References <br />  1. Urbina JA (2010) Specific chemotherapy Chagas disease: relevance, current       2. Buckner FS, Navabi N (2010) Advances Chagas disease drug development: <br />     limitations new approaches. Acta Trop 115: 55&#226;&#8364;&#8220;68.                                 2009-2010. Curr Opinion Infect Dis 23: 609&#226;&#8364;&#8220;616. <br />  <br />  <br />  <br />        PLoS Pathogens | www.plospathogens.org                                      9                      September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                                                    T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br />  3. McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson SA, et al. (2009)                       31. Hitotsumatsu O, Ahmad  Tavares RM, Wang M, Philpott D, et al. (2008) <br />     approaches discovering developing new drugs Chagas disease.                        ubiquitin-editing enzyme A20 restricts <span id='am-38' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-39' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-40' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-43' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span>nucleotide</span>-binding oligomerization <br />     Mem Inst Oswaldo Cruz 104: 263&#226;&#8364;&#8220;269.                                                               domain containing 2-triggered signals. Immunity 28: 381&#226;&#8364;&#8220;390. <br />  4. Chagas C , Coletanea Trabalhos Cientificos 1909-1913. Editora                           32. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, et al. (2010)     Universidade Brasilia. pp 237&#226;&#8364;&#8220;335.                                                             Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival Prevents <br />  5. Schuster JP, Schaub GA (2000) Trypanosoma cruzi: skin-penetration kinetics                     Autoimmunity. Immunity 33: 181&#226;&#8364;&#8220;191. <br />     vector derived metacyclic trypomastigotes. Int J Parasitol 30: 1475&#226;&#8364;&#8220;1479.                     33. Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL, et al. (2000) Preformed <br />  6. Giordanengo L, Guinazu N, Stempin C, Fretes R, Cerban FM, et al. (2002)                           membrane-associated stores interleukin  -12 previously unrecognized <br />     Cruzipain, major Trypanosoma cruzi antigen, conditions host immune                          source bioactive 12 mobilized minutes contact     response favor parasite. Eur J Immunol 32: 1003&#226;&#8364;&#8220;1011.                                       intracellular parasite. Exp Med 192: 507&#226;&#8364;&#8220;515. <br />  7. Stempin CS, Tanos TB, Coso OA, Cerba&#194;&#180;n FM (2003) Arginase induction                           34. Corraliza IM, Campo ML, Soler G, Modollel M (1994) Determination     promotes Trypanosoma cruzi intracellular replication Cruzipain-treated J774                    arginase activity macrophages: micromethod. J Immunol Methods 174: <br />     cells activation multiple signaling pathways. Eur J Immunol 34:                    231&#226;&#8364;&#8220;235. <br />     200&#226;&#8364;&#8220;209.                                                                                      35. Cameron P, McGachy  Anderson M, Paul  Coombs GH, et al. (2004) <br />  8. Tomas  Kelly JM (1994) Transformation approach functional                             Inhibition <span id='am-21' about='obo:IMR_0001655' typeof='owl:Thing obo:IMR_0001790 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0000001 obo:IMR_0001362'><span id='am-22' property="oboInOwl:id" content="IMR:0001655" datatype="xsd:string"></span><span id='am-23' property="rdfs:label" content="LPS" datatype="xsd:string"></span><span id='am-24' property="rdfs:label" content="lipopolysaccharide" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasExactSynonym" content="lipopolysaccharide" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasDbXref" content="MeSH:D008070" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasDbXref" content="KEGG:C00338" datatype="xsd:string"></span><span id='am-29' property="obo:IAO_0000115" content="Lipopolysaccharide (LPS) is a glycosylated lipid on the outer surface of Gram-negative bacteria acts as immunostimulants." datatype="xsd:string"></span><span id='am-30' property="oboInOwl:hasDbXref" content="CHEBI:16412" datatype="xsd:string"></span>lipopolysaccharide</span>-induced macrophage 12 production     analysis major cysteine protease Trypanosoma cruzi. Biochem Soc Trans                   Leishmania mexicana amastigotes: role cysteine peptidases NF- <br />     22: 90S.                                                                                          kappaB signaling pathway. J Immunol 173: 3297&#226;&#8364;&#8220;3304. <br />  9. Tomas  Kelly JM (1996) Stage-regulated expression cruzipain, major                  36. Ghosh S (1999) Regulation inducible gene expression transcription <br />     cysteine protease Trypanosoma cruzi independent level RNA. Mol                    factor NF-kB. Immunol Res 19: 183&#226;&#8364;&#8220;189. <br />     Biochem Parasitol 76: 91&#226;&#8364;&#8220;103. <br />                                                                                                   37. Hall BS, Tam W, Sen R, Pereira (2000) Cell-specific activator nuclear <br /> 10. Tomas  Miles MA, Kelly JM (1997) Overexpression cruzipain, major <br />                                                                                                       factor kappa B parasite Trypanosoma cruzi promotes resistance     cysteine proteinase Trypanosoma cruzi, associated enhanced metacyclo- <br />                                                                                                       intracellular infection. Mol Biol Cell 11: 153&#226;&#8364;&#8220;160. <br />     genesis. Eur J Biochem 244: 596&#226;&#8364;&#8220;603. <br />                                                                                                   38. Hayden MS, West AP, Ghosh S (2006) NF-kB immune response. <br /> 11. Yong V, Schmitz V, Vannier-Santos MA, Lima AP, Lalmanach G, et al. <br />                                                                                                       Oncogene 25: 6758&#226;&#8364;&#8220;6780. <br />     (2000) Altered expression cruzipain cathepsin B-like target     Trypanosoma cruzi cell line displaying resistance synthetic inhibitors cysteine-        39. Chen Y, Vallee S, Wu J, Vu D, Sondek J, et al. (2004) Inhibition NF-kB <br />     proteinases. Mol Biochem Parasitol 109: 47&#226;&#8364;&#8220;59.                                                    activity IkBb association kB-ras. Mol Cell Biol 24: 3048&#226;&#8364;&#8220;3056. <br /> 12. Lima P  dos Reis CGF, Serveau C, Lalmanach G, Juliano L, et al. (2001)                    40. DiDonato JA, Mercurio F, Karin M (1995) Phosphorylation ikBa&#194;&#180; precedes <br />     Cysteine protease isoforms Trypanosoma cruzi, cruzipain 2 cruzain,                       sufficient dissociation NF-kB. Mol Cell Biol 15: <br />     present different substrate preference susceptibility inhibitors. Mol                      1302&#226;&#8364;&#8220;1311. <br />     Biochem Parasitol 114: 41&#226;&#8364;&#8220;52.                                                                 41. Marienfeld RF, Palkowitsch L, Ghosh S (2006) Dimerization ikB kinase- <br /> 13. Lima AP, Almeida PC, Tersariol LL, Schmitz V, Schmaier AH, et al. (2002)                          binding domain NEMO required tumor necrosis factor alpha-induced <br />     Heparan sulfate modulates kinin release Trypanosoma cruzi activity                 NF-kB activity. Mol Cell Biol 26: 9209&#226;&#8364;&#8220;9219. <br />     cruzipain. J Biol Chem 277: 5875&#226;&#8364;&#8220;5881.                                                     42. Plaen  Han XB, Liu X, Hsueh W, Ghosh S, et al. (2006) <br /> 14. Scharfstein J, Schmitz V, Morandi V, Capella MM, Lima AP, et al. (2000) Host                      Lipopolysaccharide induces CXCL2/macrophage inflammatory protein-2 gene <br />     cell invasion Trypanosoma cruzi potentiated activation bradykinin B(2)                expression enterocytes NF-kB activation: independence endogenous <br />     receptors. J Exp Med 192: 1289&#226;&#8364;&#8220;1300.                                                              TNF platelet activation factor. Immunology 118: 153&#226;&#8364;&#8220;163. <br /> 15. Aoki MP, Cano RC, Pellegrini AV, Tanos T, Guinazu NL, et al. (2006)                           43. Petersen CA, Krumholz KA, Burleigh BA (2005) Toll-like receptor 2 modulates <br />     Different signaling pathways involved cardiomyocyte survival induced                    1B dependent cardiomyocyte hypertrophy triggered Trypanosoma cruzi. Inf <br />     Trypanosoma cruzi glycoprotein. Microbes Infect 8: 1723&#226;&#8364;&#8220;1731.                                   Immun 73: 6974&#226;&#8364;&#8220;6980. <br /> 16. Eakin AE, Mills AA, Harth G, McKerrow JH, Craik CS (1992) sequence,                       44. Petersen CA, Krimholz KA, Carmen J, Sinai AP, Burleigh BA (2006) <br />     organization, expression major cysteine protease (cruzain)                        Trypanosoma cruzi infection nuclear factor kappa B activation prevent <br />     Trypanosoma cruzi. J Biol Chem 267: 7411&#226;&#8364;&#8220;7420.                                                    apoptosis cardiac cells. Inf Imm 74: 1580&#226;&#8364;&#8220;1587. <br /> 17. Cazzulo JJ (1999) Cruzipain, major cysteine proteinase Trypanosoma cruzi:                  45. Ba X, Shivali Gupta S, Davidson M, Garg NJ (2010) Trypanosoma cruzi Induces <br />     sequence genomic organization codifying genes. Medicina (B Aires)                      Reactive Oxygen Species-PARP-1-RelA Pathway regulation     59: 7&#226;&#8364;&#8220;10.                                                                                         Cytokine Expression Cardiomyocytes. J Biol Chem 285: 11596&#226;&#8364;&#8220;11606. <br /> 18. Engel JC, Doyle PS, Hsieh  McKerrow JH (1998) Cysteine protease inhibitors                  46. Huang H, Calderon TM, Berman JW, Braunstein VL, Weiss LM, et al. (1999) <br />     cure experimental Trypanosoma cruzi infection. J Exp Med 188: 725&#226;&#8364;&#8220;734.                         Infection Endothelial Cells Trypanosoma cruzi Activates NF-kB 19. Duschak VG, Ciaccio M, Nassert JR, Basombrio MA (2001) Enzymatic activity,                        Induces Vascular Adhesion Molecule Expression. Infect Immun. 67: 5434&#226;&#8364;&#8220;5440. <br />     protein expression, gene sequence cruzipain virulent attenuated                 47. Wu C, Gosh S (2003) Differential phosphorylation signal-responsive <br />     Trypanosoma cruzi strains. J Parasitol 87: 1016&#226;&#8364;&#8220;1022.                                             domain ikBa ikBb IkB kinases. J Biol Chem 34: 31980&#226;&#8364;&#8220;31987. <br /> 20. Duschak VG, Riarte  Segura EL, Laucella SA (2001) Humoral immune                            48. Baeuerle PA, Baltimore D (1996) NF-kB years  Cell 87: 113&#226;&#8364;&#8220;120. <br />     response cruzipain cardiac dysfunction chronic Chagas&#226;&#8364;&#8482; disease.                     49. Israel  Kroemer G (2006) NF-kB life/death decisions: introduction. <br />     Immunol Letters 78: 135&#226;&#8364;&#8220;142.                                                                      Cell Death Differ 13: 685&#226;&#8364;&#8220;686. <br /> 21. Paiva CN, Souto-Padron T, Costa DA, Gattass CR (1998) High expression                    50. Perkins ND, Gilmore TD (2006) Good cop, bad cop: different faces NF- <br />     functional cruzipain non-infective non-pathogenic Trypanosoma cruzi                      kB. Cell Death Differ 13: 759&#226;&#8364;&#8220;772. <br />     clone. Parasitology 117: 483&#226;&#8364;&#8220;940.                                                             51. Liou HC, Hsia CY (2003) Distinctions c-Rel NF-kB proteins <br /> 22. Engel JC, Torres Garcia C, Hsieh  Doyle PS, McKerrow JH (2000)                                  immunity disease. Bioassays 25: 767&#226;&#8364;&#8220;780. <br />     Upregulation secretory pathway cysteine protease inhibitor-resistant                52. Nelson  Ihekwaba AEC, Elliot M, Johnson JR, Gibney CA, et al. (2004) <br />     Trypanosoma cruzi. J Cell Science 113: 1345&#226;&#8364;&#8220;1354. <br />                                                                                                       Oscillations NF-kB signaling control dynamics gene expression. Science <br /> 23. Engel JC, Doyle PS, Dvorak JA (1985) Trypanosoma cruzi: Biological <br />                                                                                                       306: 704&#226;&#8364;&#8220;708. <br />     characterization clones derived chronic chagasic patients. II. <br />                                                                                                   53. Nascimento AE, Souza W (1996) High resolution localization cruzipain <br />     Quantitative analysis intracellular cycle. J Protozool 32: 80&#226;&#8364;&#8220;83. <br />                                                                                                       Ssp4 Trypanosoma cruzi replica staining label fracture. Biol Cell 86: <br /> 24. Engel JC, Doyle PS, Palmer J, Hsieh  Bainton DF, et al. (1998) Cysteine <br />                                                                                                       53&#226;&#8364;&#8220;58. <br />     protease inhibitors alter Golgi complex ultrastructure function     Trypanosoma cruzi. J Cell Sci 111: 597&#226;&#8364;&#8220;606.                                                   54. Burleigh BA, Andrews NW (1995) mechanisms Trypanosoma cruzi invasion <br /> 25. Engel JC, Cazzulo BMF, Stoppani OAM, Canatta JJB, Cazzulo JJ (1987)                            mammalian cells. Ann Rev Microbiol 49: 175&#226;&#8364;&#8220;200. <br />     Aerobic glucose fermentation Trypanosoma cruzi axenic culture amastigote-like              55. Burleigh BA (2005) Host cell signaling Trypanosoma cruzi invasion:     forms growth differentiation epimastigotes. Mol Bioch Parasitol                     roads lead lysosomes? Sci STKE 293: 36&#226;&#8364;&#8220;43. <br />     26: 1&#226;&#8364;&#8220;10.                                                                                     56. Ley V, Andrews NW, Robbins ES, Nussenzweig V (1998) Amastigotes 26. Doyle PS, Dvorak JA, Engel JC (1984) Trypanosoma cruzi: Quantification                        Trypanosoma cruzi sustain infective cycle mammalian cells. J Exp Med 168: <br />     analysis infectivity cloned stocks. J Protozool 31: 280&#226;&#8364;&#8220;283.                            649&#226;&#8364;&#8220;659. <br /> 27. Bogyo M, Verhelst S, Bellingard-Dubouchaud V, Toba S, Greenbaum DC                            57. Kima PE, Burleigh BA, Andrews NW (2000) Surface-targeted lysosomal <br />     (2000) Selective targeting lysosomal cysteine proteases radiolabeled                      membrane glyocoprotein-1 (Lamp-1) enhances lysosome exocytosis cell <br />     electrophilic substrate analogs. Chem Biol 7: 27&#226;&#8364;&#8220;38.                                              invasion Trypanosoma cruzi. Cell Microbiol 2: 477&#226;&#8364;&#8220;486. <br /> 28. Greenbaum DC, Medzihradszky KF, Burlingame  Bogyo M (2000) Epoxide                          58. Gaur U, Roberts SC, Dalvi RP, Corraliza  Ullman B, et al. (2007) Effect     electrophiles activity-dependent cysteine protease profiling discovery                     Parasite-Encoded Arginase Outcome Murine Cutaneous Leishman- <br />     tools. Chem Biol 7: 569&#226;&#8364;&#8220;581.                                                                      iasis. J Immunol 179: 8446&#226;&#8364;&#8220;8453. <br /> 29. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ (2000) Cutting edge:                           59. Campos MA, Closel M, Valente EP, Cardoso JE, Akira S, et al. (2004) Impaired <br />     repurification lipopolysaccharide eliminates signaling human                      production proinflammatory cytokines host resistance acute infection <br />     murine toll-like receptor 2. J Immunol 165: 618&#226;&#8364;&#8220;622.                                          Trypanosoma cruzi mice lacking functional myeloid differentiation factor <br /> 30. Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, et al. (2008)                       88. J Immunol 172: 1711&#226;&#8364;&#8220;1718. <br />     Homeostatic MyD88-dependent signals cause lethal inflammation                          60. Gordon S (2003) Alternative activation macrophages. Nature Rev Immunol 3: <br />     absence A20. J Exp Med 205: 451&#226;&#8364;&#8220;464.                                                           23&#226;&#8364;&#8220;35. <br />  <br />  <br />  <br />          PLoS Pathogens | www.plospathogens.org                                              10                         September 2011 | Volume 7 | Issue 9 | e1002139 <br />                                                                                                                               T. cruzi Protease Mediates Immune Evasion <br />  <br />  <br /> 61. Noe&#194;&#168;l W, Raes G, Ghassabeh GH, Baetselier P, Beschin (2004)                         70. Bergeron M, Olivier M (2006) Trypanosoma cruzi-Mediated IFN-Inducible Nitric <br />     Alternatively activated macrophages parasite infections. Tr Parasitol                 Oxide Output Macrophages Regulated iNOS mRNA Stability. <br />     20: 126&#226;&#8364;&#8220;133.                                                                                 J Immunol 177: 6271&#226;&#8364;&#8220;80. <br /> 62. Zhang S, Kim CC, Batra S, McKerrow JH, Loke P (2010) Delineation diverse              71. Huang H, Petkova SB, Cohen AW, Bouzahzah B, Chan J, et al. (2003) <br />     macrophage activation programs response intracellular parasites                    Activation transcription factors AP-1 NF-kB murine chagasic <br />     cytokines. PLoS Negl Trop Dis 4: e648.                          <br /> </body></html>